<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00770471</url>
  </required_header>
  <id_info>
    <org_study_id>NABTT-0801 CDR0000616542</org_study_id>
    <secondary_id>U01CA062475</secondary_id>
    <secondary_id>ABTC-0801</secondary_id>
    <secondary_id>NABTT-0801</secondary_id>
    <secondary_id>ABBOTT-M10-190</secondary_id>
    <nct_id>NCT00770471</nct_id>
  </id_info>
  <brief_title>ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme</brief_title>
  <official_title>A Phase I/II Trial of Temozolomide and ABT-888 in Subjects With Newly Diagnosed Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: ABT-888 may stop the growth of tumor cells by blocking some of the enzymes needed&#xD;
      for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in&#xD;
      chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells,&#xD;
      either by killing the cells or by stopping them from dividing. Giving ABT-888 together with&#xD;
      radiation therapy and temozolomide may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of ABT-888 when&#xD;
      given together with radiation therapy and temozolomide and to see how well it works in&#xD;
      treating patients with newly diagnosed glioblastoma multiforme.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the maximum tolerated dose (MTD) of ABT-888 when administered in&#xD;
           combination with radiotherapy and temozolomide in patients with newly diagnosed&#xD;
           glioblastoma multiforme. (Phase I)&#xD;
&#xD;
        -  To estimate the overall survival of patients treated with ABT-888 when administered at&#xD;
           the MTD in combination with radiotherapy and temozolomide. (Phase II)&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To assess the toxicity associated with this regimen. (Phase I)&#xD;
&#xD;
        -  To assess and describe the pharmacokinetics of ABT-888. (Phase I)&#xD;
&#xD;
        -  To estimate the frequency of toxicity associated with this regimen. (Phase II)&#xD;
&#xD;
      OUTLINE: This is a multicenter, phase I dose-escalation study of ABT-888 followed by a phase&#xD;
      II study.&#xD;
&#xD;
        -  Initiation therapy: Patients receive oral ABT-888 twice daily (once on day 1 only) and&#xD;
           oral temozolomide once daily (beginning on day 2) in weeks 1-6. Patients enrolled in the&#xD;
           phase I dose-escalation/phase II portion of the study also undergo concurrent&#xD;
           radiotherapy once daily 5 days a week (beginning on day 2) in weeks 1-6. Treatment&#xD;
           continues in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Maintenance therapy: Beginning 4 weeks after completion of initiation therapy, patients&#xD;
           receive oral ABT-888 twice daily on days 1-7 and oral temozolomide once daily on days&#xD;
           1-5. Treatment repeats every 28 days for up to 4 courses (6 courses for patients&#xD;
           enrolled in the phase I dose-escalation/phase II portion of the study) in the absence of&#xD;
           disease progression or unacceptable toxicity.&#xD;
&#xD;
      Blood samples are collected periodically for pharmacokinetic, pharmacogenetic, and&#xD;
      pharmacodynamic analysis. Samples are analyzed for concentration of ABT-888 in plasma by&#xD;
      reversed-phase isocratic high performance liquid chromatography with electrospray ionization&#xD;
      mass spectrometry; identification of novel markers of treatment response by plasma proteomic&#xD;
      evaluation; DNA methylation and/or mutation; and PARP inhibition by ELISA.&#xD;
&#xD;
      After completion of study therapy, patients are followed every 2 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 13, 2009</start_date>
  <completion_date type="Actual">March 1, 2012</completion_date>
  <primary_completion_date type="Actual">March 1, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of ABT-888 (Phase I)</measure>
    <time_frame>continous</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (Phase II)</measure>
    <time_frame>continous</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity (Phase I)</measure>
    <time_frame>continous</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ABT-888 (Phase I)</measure>
    <time_frame>continous</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of toxicity (Phase II)</measure>
    <time_frame>continous</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <arm_group>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
    <arm_group_label>Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>veliparib</intervention_name>
    <arm_group_label>Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA methylation analysis</intervention_name>
    <arm_group_label>Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
    <arm_group_label>Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>mutation analysis</intervention_name>
    <arm_group_label>Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>proteomic profiling</intervention_name>
    <arm_group_label>Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>high performance liquid chromatography</intervention_name>
    <arm_group_label>Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunoenzyme technique</intervention_name>
    <arm_group_label>Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <arm_group_label>Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mass spectrometry</intervention_name>
    <arm_group_label>Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacogenomic studies</intervention_name>
    <arm_group_label>Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <arm_group_label>Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
    <arm_group_label>Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>Dose Escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed supratentorial grade IV astrocytoma (glioblastoma multiforme)&#xD;
&#xD;
               -  Newly diagnosed disease&#xD;
&#xD;
          -  Patients enrolled in the phase I initial safety portion of the study must meet the&#xD;
             following additional criteria:&#xD;
&#xD;
               -  Received 90% of planned radiotherapy and ≥ 80% of planned concurrent temozolomide&#xD;
                  within the past 28-49 days&#xD;
&#xD;
                    -  No grade 3-4 toxicity attributed to temozolomide&#xD;
&#xD;
               -  Has undergone gadolinium MRI or contrast CT scan within the past 28 days&#xD;
&#xD;
          -  Patients enrolled in the phase I dose-escalation/phase II portion of the study must&#xD;
             meet the following additional criteria:&#xD;
&#xD;
               -  Recovered from immediate post-operative period and maintained on a stable&#xD;
                  corticosteroid regimen (no increase in 5 days) prior to starting study treatment&#xD;
&#xD;
               -  Has undergone gadolinium MRI or contrast CT scan within the past 14 days&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status 60-100%&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  ANC ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL OR creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  Transaminases ≤ 2.5 times upper limit of normal&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception prior to, during, and for 3 months&#xD;
             after completion of study therapy&#xD;
&#xD;
          -  Mini Mental State Exam score ≥ 15&#xD;
&#xD;
          -  Able to swallow and retain oral medications&#xD;
&#xD;
          -  No concurrent serious infection or medical illness that would jeopardize the ability&#xD;
             of the patient to receive study treatment with reasonable safety&#xD;
&#xD;
          -  No other malignancy within the past 5 years except for curatively treated carcinoma in&#xD;
             situ or basal cell carcinoma of the skin&#xD;
&#xD;
          -  No known uncontrolled seizure disorder (i.e., status epilepticus) or seizures&#xD;
             occurring ≥ 3 times per week over the past month&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 10 days since prior cytochrome P450-inducing anticonvulsants (e.g.,&#xD;
             phenytoin, carbamazepine, phenobarbital, primidone, or oxcarbazepine)&#xD;
&#xD;
          -  At least 1 week since prior biopsy or resection of tumor (for patients enrolled in the&#xD;
             phase I dose-escalation/phase II portion of the study)&#xD;
&#xD;
          -  No prior radiotherapy, chemotherapy, immunotherapy, hormonal therapy, or biological&#xD;
             therapy (including immunotoxins, immunoconjugates, antisense therapy, peptide receptor&#xD;
             antagonists, interferons, interleukins, tumor-infiltrating lymphocytes,&#xD;
             lymphokine-activated killer cells, or gene therapy) for treatment of brain tumor (for&#xD;
             patients enrolled in the phase I dose-escalation/phase II portion of the study)&#xD;
&#xD;
               -  Prior glucocorticoid therapy allowed&#xD;
&#xD;
          -  No other prior chemotherapy or investigational agents (for patients enrolled in the&#xD;
             phase I initial safety portion of the study)&#xD;
&#xD;
          -  Prior Gliadel wafers allowed (for patients enrolled in the phase I portion of the&#xD;
             study)&#xD;
&#xD;
          -  No prior Gliadel wafers (for patients enrolled in the phase II portion of the study)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Larry Kleinberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UAB Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josephine Ford Cancer Center at Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Cancer Centers</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-6164</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>October 9, 2008</study_first_submitted>
  <study_first_submitted_qc>October 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2008</study_first_posted>
  <last_update_submitted>June 25, 2018</last_update_submitted>
  <last_update_submitted_qc>June 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Veliparib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

